Publications by authors named "A PIERRE"
Background: Given advancements in adjuvant treatments for non-small-cell lung cancer (NSCLC) with epidermal growth factor receptor (EGFR) and anaplastic lymphoma kinase (ALK)-targeted therapies, it is important to consider postoperative targeted therapies for other early-stage oncogene-addicted NSCLC. Exploring baseline outcomes for early-stage NSCLC with these rare mutations is crucial.
Objectives: This study aims to assess relapse-free survival (RFS) and overall survival (OS) in patients with resected early-stage NSCLC with rare targetable driver mutations.
Effectiveness and Safety of Direct-Acting Antivirals in the Treatment of Chronic Hepatitis C: A Real-life Study in Northeastern Brazil.
Rev Soc Bras Med Trop
November 2024
Article Synopsis
- The study evaluated the effectiveness and safety of direct-acting antivirals (DAAs) for hepatitis C, focusing on sustained virologic response (SVR) and serious adverse events among patients in Ceará, Brazil.
- A total of 1075 patients were analyzed, with a high overall SVR rate of 96.4%; however, those with cirrhosis showed slightly lower SVR rates compared to patients with less severe fibrosis.
- While DAAs were generally safe, a small percentage (3.5%) of patients experienced serious adverse events, and some decompensated cirrhosis patients faced mortality during treatment.
Lipoprotein(a), or Lp(a), is encoded by the LPA gene and is a causal genetic risk factor for cardiovascular disease. Individuals with high Lp(a) are at risk for cardiovascular morbidity and are refractory to standard lipid-lowering agents. Lp(a)-lowering therapies currently in clinical development require repetitive dosing, while a gene editing approach presents an opportunity for a single-dose treatment.
View Article and Find Full Text PDFPurpose: Cardiac rehabilitation (CR) is beneficial in heart transplant and left ventricular assist device (LVAD) recipients, but patterns of attendance remain poorly understood. We describe CR adherence and cessation in this population.
Methods: We performed a retrospective review of heart transplant and LVAD recipients who attended ≥1 CR session at a tertiary medical center (2013-2022).